C. Scott McMillin | Recovery SI

Focus on Demand

Posted by C. Scott McMillin | Oct 3, 2016 | Public Policy | 0 |

Many new programs are started in the hopeful expectation that they’ll become self-supporting within a few years.

There are just too many ways to get drugs across borders for a fence or a wall to make that much difference.

Despite the collateral damage, Big Pharma seems determined to preserve the market for its products, through sophisticated lobbying.

From a patient’s viewpoint, physicians can be somewhat blase’ about risks associated with a medication.

It may be that kratom is a drug that some can use without much difficulty, while for others, it becomes pathological.